Fiona Marshall (pharmacologist)

Last updated

Fiona Marshall
Fiona Marshall at NIH's 2017 Daly lecture.jpg
Marshall speaking at the National Institutes of Health 2017 Daly lecture
Born
Fiona Hamilton Marshall
Alma mater University of Bath (BSc)
University of Cambridge (PhD)
Scientific career
Fields Drug discovery
GPCRs
Neuroscience [1] [2]
Institutions Merck & Co.
GlaxoSmithKline
Thesis Cholecystokinin/dopamine interactions in the rat basal ganglia  (1990)
Doctoral advisor John Hughes

Fiona Hamilton Marshall FRS FMedSci is a British pharmacologist, founder and Senior Vice President of Discovery, Preclinical & Translational Medicine at Merck & Co. She will become the next president of the Novartis Institutes for BioMedical Research. [3] She previously served as Chief Scientific Officer at Heptares Therapeutic, [2] where she was Vice President of the Japanese biopharmaceutical company Sosei. [1] She was elected Fellow of the Academy of Medical Sciences in 2016 [4] and the Royal Society in 2021. [5]

Contents

Early life and education

Marshall became interested in biology, chemistry and physics at high school. [6] As a teenager she won a prize at a national physics competition. Marshall graduated with a First class degree in biochemistry from the University of Bath in 1987. [7] She moved to the University of Cambridge for her graduate studies, [8] where she focussed on neuroscience under the supervision of John Hughes. [8] Her doctoral advisor served as director of the University of Cambridge Parke-Davis Research Centre, which inspired Marshall to work in the pharmaceutical industry. [7]

Research and career

After earning her doctorate Marshall moved to GlaxoSmithKline where she joined the department of neuropharmacology. Marshall worked alongside Patrick Humphrey and Mike Tyers at GlaxoSmithKline. Here she investigated the receptors that are activated by neurotransmitters and microbial metabolites. [9] After only nine years, Marshall was made Head of Molecular Pharmacology in 1999. [7] She eventually moved from the neuropharmacology team to a group working on G protein-coupled receptors. [7] Almost a third of drugs work through these G protein-coupled receptors. [6] She was the first to identify and describe the cloning and structural requirements of the GABAB receptor, a member of the GPCR family. She was headhunted by Millennium Pharmaceuticals and joined as their Director of Molecular Pharmacology in 2000. [7] When her children were young, Marshall took time out of her work at GlaxoSmithKline to work more flexibly. [6]

Working with Malcolm Weir, and together with Christopher Tate and Richard Henderson, Marshall founded Heptares Therapeutics, [10] a spin-out from the Medical Research Council (MRC). [11] Heptares makes use of technologies developed by the Medical Research Council that allow the crystallisation and characterisation of G protein-coupled receptors. One of the cancer therapy drug candidates developed by Heptares was licensed to AstraZeneca in 2015. Later that year, Heptares was incorporated into the Japanese biopharmaceutical company Sosei. [6] [2]

Marshall joined Merck & Co as Head of the Discovery Research Centre in 2018. In this capacity she concentrated on diseases of ageing. In 2019 she was made Head of Neuroscience Discovery, where she spent two years before being appointed Senior Vice President of Discovery, Preclinical & Translational Medicine Research. [12] She serves on the council of the Academy of Medical Sciences and the Medical Research Council.

Awards and honours

Selected publications

Related Research Articles

<span class="mw-page-title-main">GABA receptor</span> Receptors that respond to gamma-aminobutyric acid

The GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory compound in the mature vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels ; whereas GABAB receptors are G protein-coupled receptors, also called metabotropic receptors.

<span class="mw-page-title-main">Richard Henderson (biologist)</span> British biologist

Richard Henderson is a British molecular biologist and biophysicist and pioneer in the field of electron microscopy of biological molecules. Henderson shared the Nobel Prize in Chemistry in 2017 with Jacques Dubochet and Joachim Frank. "Thanks to his work, we can look at individual atoms of living nature, thanks to cryo-electron microscopes we can see details without destroying samples, and for this he won the Nobel Prize in Chemistry."

Dame Frances Mary Ashcroft is a British ion channel physiologist. She is Royal Society GlaxoSmithKline Research Professor at the University Laboratory of Physiology at the University of Oxford. She is a fellow of Trinity College, Oxford, and is a director of the Oxford Centre for Gene Function. Her research group has an international reputation for work on insulin secretion, type II diabetes and neonatal diabetes. Her work with Andrew Hattersley has helped enable children born with diabetes to switch from insulin injections to tablet therapy.

<span class="mw-page-title-main">GABBR1</span> Protein-coding gene in the species Homo sapiens

Gamma-aminobutyric acid B receptor, 1 (GABAB1), is a G-protein coupled receptor subunit encoded by the GABBR1 gene.

Gillian Patricia Bates FMedSci FRS is a British biologist. She is distinguished for her research into the molecular basis of Huntington's disease and in 1998 was awarded the GlaxoSmithKline Prize as a co-discoverer of the cause of this disease. As of 2016, she is Professor of Neurogenetics at UCL Institute of Neurology and the co-director of UCL Huntington's Disease Centre.

Charon Robin Ganellin FRS is a British medicinal chemist, and Emeritus Smith Kline and French Professor of Medicinal Chemistry, at University College London.

<span class="mw-page-title-main">Stuart Cull-Candy</span> British neuroscientist

Stuart Graham Cull-Candy is a British neuroscientist. He holds the Gaddum Chair of Pharmacology and a personal Chair in Neuroscience at University College London. He is also a member of the Faculty of 1000 and held a Royal Society - Wolfson Research position.

Ann Jacqueline Hunter CBE FMedSci FBPharmacolS FRSB is a British scientist who is a board director of BenevolentAI. Hunter is also a visiting professor at St George's Hospital Medical School and Imperial College. She is Chair of the Trustees of the Sainsbury Laboratories at Norwich, chair of the board of the Stevenage Bioscience Catalyst and chair of the board of Brainomix. She was previously CEO of the Biotechnology and Biological Sciences Research Council.

<span class="mw-page-title-main">Jane Clarke (scientist)</span> English biochemist and academic

Jane Clarke is an English biochemist and academic. Since October 2017, she has served as President of Wolfson College, Cambridge. She is also Professor of Molecular Biophysics, a Wellcome Trust Senior Research Fellow in the Department of Chemistry at the University of Cambridge. She was previously a Fellow of Trinity Hall, Cambridge. In 2023, she was elected to the National Academy of Sciences.

<span class="mw-page-title-main">Annette Dolphin</span> Professor of Pharmacology

Annette Catherine Dolphin is a Professor of Pharmacology in the Department of Neuroscience, Physiology and Pharmacology at University College London (UCL).

<span class="mw-page-title-main">Ben G. Davis</span> Professor of Chemistry, in the Department of Chemistry at the University of Oxford

Benjamin Guy Davis is Professor of Chemical biology in the Department of Pharmacology and a member of the Faculty in the Department of Chemistry at the University of Oxford and a Fellow of Pembroke College, Oxford. He holds the role of Science Director for Next Generation Chemistry (2019-2024) and Deputy Director (2020-) at the Rosalind Franklin Institute.

<span class="mw-page-title-main">Antony Galione</span> British pharmacologist (born 1963)

Antony Giuseppe Galione is a British pharmacologist. He is a professor and Wellcome Trust senior investigator in the Department of Pharmacology at the University of Oxford.

<span class="mw-page-title-main">David Lodge (scientist)</span> British neuroscientist

David Lodge is a research fellow in the Department of Physiology and Pharmacology at the University of Bristol.

Professor Norman Bowery, was a British pharmacologist and former Head of Division of Neuroscience and Chair of Pharmacology at the University of Birmingham from 1995 to 2004. He was president of the British Pharmacological Society from 1995 to 1997 and from 1999 to 2000.

Professor Patrick Humphrey OBE DSc PhD HonFBPhS is a South African-born British pharmacologist. He was instrumental in the discovery of the triptans, a group of 5-HT1B and 5-HT1D agonists used to stop single instances of cluster headache or migraine.

Julia Clare Buckingham is a British pharmacologist, academic and academic administrator. She is the former Vice Chancellor of Brunel University London, UK.

Sir Colin Terence Dollery was a clinical pharmacologist who spent much of his life working for SmithKline Beecham and its successor, Glaxo Smith Kline. He was knighted in the Queen's 1987 birthday honours. He was an honorary fellow of the British Pharmacological Society and a fellow of the Academy of Medical Sciences.

<span class="mw-page-title-main">3-APPA</span> Chemical compound

3-Aminopropylphosphinic acid, also known in the literature as 3-APPA or CGP 27492, is a compound used in scientific research which acts as an agonist at the GABAB receptor. It is part of a class of phosphinic acid GABAB agonists, which also includes SKF-97,541. It has a binding affinity (pKi) to the GABAB receptor of 8.30.

Clare Bryant FLSW is a British veterinary scientist and clinical pharmacologist who is a professor at the University of Cambridge. She specialises in innate immunity. Bryant is a Fellow of Queens' College, Cambridge and of the British Pharmacological Society.

Arthur Henry Weston is emeritus professor at the University of Manchester, where he was previously Leech Professor of Pharmacology from 1989-2011.

References

  1. 1 2 Fiona Marshall publications indexed by Google Scholar OOjs UI icon edit-ltr-progressive.svg
  2. 1 2 3 Fiona Marshall publications from Europe PubMed Central
  3. Carroll, John. "NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall". Endpoints News. Retrieved 1 September 2022.
  4. "Dr Fiona Marshall | The Academy of Medical Sciences". acmedsci.ac.uk.
  5. 1 2 Anon (2021). "Fiona Marshall". royalsociety.org. Royal Society. Retrieved 14 May 2021.
  6. 1 2 3 4 5 "Meet the infocus ambassadors - Fiona Marshall - Innovate UK". innovateuk.blog.gov.uk. Retrieved 14 May 2021.
  7. 1 2 3 4 5 6 "Dr Fiona Marshall FMedSci, FBPhS, FRSB: oration". bath.ac.uk. Retrieved 14 May 2021.
  8. 1 2 Marshall, Fiona Hamilton (1990). Cholecystokinin/dopamine interactions in the rat basal ganglia. cam.ac.uk (PhD thesis). University of Cambridge. OCLC   82547258. EThOS   uk.bl.ethos.386170.
  9. 1 2 Therapeutics, Heptares. "Heptares Chief Scientific Officer and Co-founder - Dr Fiona Marshall - Elected as a Fellow of the Academy of Medical Sciences". prnewswire.com (Press release). Retrieved 14 May 2021.
  10. Mike, Scialom (19 October 2018). "It's a new day for Sosei Heptares". Cambridge Independent. Retrieved 28 September 2023.
  11. 1 2 "Dr Fiona Marshall". bps.ac.uk.
  12. "Fiona Marshall elected a fellow of the Royal Society". msd.com. Retrieved 14 May 2021.
  13. "Malcolm Campbell Memorial Prize winners 2015 – RSC Medicinal Chemistry Blog". rsc.org. Retrieved 14 May 2021.
  14. "BPS Vane Medal". bps.ac.uk. British Pharmacological Society.